CytoArm CO., LTD.
Update:2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
CytoArm’s flagship technology is its Armed-T™ cell therapy, which uses a non-viral manufacturing process to produce tumor-specific T cells with over 90% purity in around 10 days. The platform is highly adaptable, with the potential to develop treatments f
Founded Year
2020
Unified Business No.
83469938
Status
Active
Number of Employees
0
Total Paid-in
Capital
36,700,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
CytoArm Co., Ltd. is a Taiwan-based biotech company focused on next-generation T cell therapies. Leveraging its proprietary Armed-T™ platform, CytoArm equips T cells with bi-functional antibodies (BsAb) to enable precise tumor targeting, all without using